Yun Zhong
Stock Analyst at Wedbush
(1.28)
# 2,899
Out of 4,667 analysts
25
Total ratings
44.44%
Success rate
-7.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $49.64 | +47.06% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $4.94 | +143.16% | 1 | Nov 5, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $58 | $41.81 | +38.72% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.52 | +228.64% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $2.03 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $9.49 | +68.69% | 1 | Jan 18, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $160 | $110.01 | +45.44% | 11 | Dec 22, 2022 | |
| RCKT Rocket Pharmaceuticals | Initiates: Buy | $35 | $12.91 | +171.11% | 1 | Nov 1, 2022 | |
| BLUE bluebird bio | Downgrades: Hold | $35 | $0.30 | +11,648.91% | 2 | Jul 1, 2021 | |
| QURE uniQure | Initiates: Buy | $46 | $5.71 | +705.60% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $0.52 | +4,698.46% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.61 | +177.01% | 1 | May 5, 2021 |
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $49.64
Upside: +47.06%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $4.94
Upside: +143.16%
Protagonist Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $58
Current: $41.81
Upside: +38.72%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.52
Upside: +228.64%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.03
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $9.49
Upside: +68.69%
Sarepta Therapeutics
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $110.01
Upside: +45.44%
Rocket Pharmaceuticals
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $12.91
Upside: +171.11%
bluebird bio
Jul 1, 2021
Downgrades: Hold
Price Target: $35
Current: $0.30
Upside: +11,648.91%
uniQure
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $5.71
Upside: +705.60%
Jun 15, 2021
Initiates: Buy
Price Target: $25
Current: $0.52
Upside: +4,698.46%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $3.61
Upside: +177.01%